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Objective: To investigate the long-term eﬀects of combination therapy with anti-
arrhythmic agents and pravastatin (10mg/day) in maintaining sinus rhythm in patients with
paroxysmal atrial ﬁbrillation (AF) and hyperlipidemia.
Method and Results: In all, 318 patients (mean age: 69 12 years) with paroxysmal AF
were divided into 2 groups, one receiving pravastatin for hyperlipidemia (pravastatin (+)
group, N = 41) and the other not (pravastatin () group, N = 277). At 60 months, the
survival rate for patients free from conversion to permanent AF was signiﬁcantly greater in
the pravastatin (+) group than in the pravastatin () group. The percentage of patients who
eventually developed permanent AF despite anti-arrhythmic therapy was signiﬁcantly lower
in the pravastatin (+) group than in the pravastatin () group (9.8% vs. 25.3%). Left atrial
dimensions were signiﬁcantly increased in the pravastatin () group during the follow-up
period (from 34:8 6:6mm to 37:6 7:0mm: p < 0.01). In contrast, in the pravastatin (+)
group, left atrial dimensions remained unchanged between baseline and after treatment
(34:4 7:3mm vs 35:5 6:6mm).
Conclusion: In patients with paroxysmal AF and hyperlipidemia, addition of pravastatin to
anti-arrhythmic agents seems to enhance the eﬃcacy of these agents in maintaining sinus
rhythm and preventing the development of structural remodeling in the myocardium.
(J Arrhythmia 2007; 23: 124–130)
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Introduction
Atrial ﬁbrillation (AF) is the most commonly
encountered tachycardia in daily medical practice.
As the incidence of AF increases rapidly with age,
the number of patients with AF is predicted to
increase with the expanding elderly population in
Japan,1) AF is an important disease from a health
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economics point of view. Furthermore, it not only
causes severe complications such as thromboembo-
lism and heart failure2) but also worsens cardiovas-
cular prognosis, especially in patients with cardiac
dysfunction.3) AF is recognized as a disease in which
long-term treatment and follow-up is required.
Atrial biopsy of patients with lone AF reveals
histopathological developments such as inﬂamma-
tory cell inﬁltration, necrosis, and ﬁbrosis.4) Plasma
concentrations of high-sensitivity C-reactive protein
(hs-CRP), which reﬂect the degree of inﬂammation,
are signiﬁcantly elevated in these patients compared
with those in normal sinus rhythm.5,6) Combination
therapy with statins and anti-arrhythmic agents
has been shown to decrease the incidence of AF
complicated with ischemic heart disease7) and the
recurrence of the persistent form of AF after
cardioversion.8) The pharmacological mechanism of
statins in this setting is believed to involve an anti-
inﬂammatory action.5,6) It has been suggested that
inﬂammation of atrial muscle provokes and prolongs
AF. The inﬂammation of atrial muscle in patients
with paroxysmal AF has been suggested to be lesser
in degree than in those with permanent AF according
to plasma concentrations of hs-CRP.5,6) However, it
remains unclear whether combination statin and anti-
arrhythmic agent therapy elicits beneﬁcial eﬀects in
patients with paroxysmal AF.
In the present study, we retrospectively examined
the long-term eﬀects of combination therapy with
anti-arrhythmic agents and pravastatin in patients
with paroxysmal AF.
Subjects and Method
Subjects
The study was performed from June 1993 to
August 2004, with a mean follow-up period of
48:4 31:0 months. Subjects were 318 patients with
symptomatic paroxysmal AF (men: 221; women: 97;
mean age: 69 12 years) who visited our hospital to
seek treatment for subjective symptoms such as
palpitation which were interfering with their daily
quality of life. All subjects were regular outpatients
who visited our hospital every 2–4 weeks. All
patients analyzed had undergone therapy to attempt
maintenance of sinus rhythm for 12 months.
Subjects were divided into 2 groups, one of which
received paravastatin for hyperlipidemia (10mg/
day, pravastatin (+); N = 41) and the other not
(pravastatin (); N = 277).
Patients with the following conditions were
excluded: congestive heart failure, severe bradycar-
dia (sick sinus syndrome, atrioventricular block,
intraventricular conduction disturbance), left ven-
tricular ejection fraction (LVEF) <40% as deter-
mined by echocardiography, liver and/or renal
dysfunction with abnormal laboratory test values,
and pregnancy. Those concomitantly receiving -
blocker and/or T-type calcium antagonist or having
other serious complications were also excluded.
Method
According to the American Heart Association
(AHA) guidelines,9) pharmacological or electrical
cardioversion under intravenous anesthesia with
thiopental was performed immediately for patients
in whom the duration of AF was <48 hrs. Before the
AHA guidelines were recommended, cardioversion
was performed with subsequent warfarin anti-coag-
ulation therapy after conﬁrmation that neither ex-
istence of thrombus in the left atrium nor sponta-
neous echo contrast was detected on transesophageal
echocardiography (TEE). For AF cases occurring
after the AHA guidelines were issued, warfarin anti-
coagulation therapy was administered for 3 weeks
prior to and 4 weeks after electrical cardioversion.
The warfarin dose was set so as to obtain an
international normalized ratio between 1.6 and 2.6.
After sinus rhythm was restored following phar-
macological or electrical cardioversion, one of the
following class Ia or Ib anti-arrhythmic agents
(disopyramide 300mg/day, aprindine 60mg/day,
or cibenzoline 300mg/day) was randomly selected
by an envelope method as the ﬁrst-line agent and
administered orally. Individual subjects were then
monitored carefully for recurrence of paroxysmal
AF. When paroxysmal AF recurred during the
follow-up period, cardioversion was immediately
performed and one of the class Ic anti-arrhythmic
agents (ﬂecainide 150mg/day, pilsicanide 150mg/
day), or bepridil 150mg/day was randomly selected
by an envelope method as the second-line agent.
Patients in whom paroxysmal AF recurred after
receiving the second agent were given either a class I
anti-arrhythmic agent that had not been used before
or amiodarone. The selection of the third-line agent
was left to the decision of the physician. At 2–4
weeks after administration of the anti-arrhythmic
agent, 12-lead electrocardiogram and ambulatory 24-
h electrocardiogram were recorded in all subjects
and it was conﬁrmed that sinus rhythm was main-
tained at each hospital visit. Once sinus rhythm was
being maintained without recurrence of paroxysmal
AF after administration of the anti-arrhythmic agent,
venous blood was collected from an upper extremity
with the subject in a resting recumbent position
to assay plasma concentrations of atrial natriuretic
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peptide (ANP) and C-reactive protein (CRP) during
sinus rhythm.
Deﬁnition and Statistical Analysis
Paroxysmal AF was deﬁned as AF terminating
spontaneously within 7 days of onset. The history
of AF was the period from the initial episode of
paroxysmal AF to the time of the initiation of anti-
arrhythmic therapy. Permanent AF was deﬁned as
AF that was refractory to pharmacological and
electrical cardioversion and did not convert to sinus
rhythm for a period greater than 6 months. Cerebral
thromboembolism was diagnosed in all cases based
on typical symptoms and the development of a new
low-density lesion greater than 3mm on CT or MRI
images of the head. Hypertension was deﬁned as
a casual blood pressure greater than 140mmHg at
systole or 90mmHg at diastole.10) Hyperlipidemia
was deﬁned as a fasting cholesterol concentration
greater than 220mg/dl and a fasting plasma con-
centration of acylglycerol greater than 150mg/dl.11)
Paroxysmal AF was divided into three groups;
diurnal type (7:00AM to 5:00PM), nocturnal type
(5:00PM to 7:00AM), and mixed type (symptoms
appearing at any time) based on the time of
equivalent symptom onset on ECG recording.12)
All data are shown as mean  S.D. Clinical
characteristics and the numbers of recurrences of
AF in individual patients were compared between
the 2 groups by unpaired t-test for continuous
variables and by the chi-square test for categorical
variables. The parameters determined by echocar-
diography were compared by paired t-test for
continuous variables. In all tests, a p-values of
<0:05 was considered a signiﬁcant diﬀerence.
Results
Clinical Characteristics of Patients
As shown in Table 1, no signiﬁcant diﬀerences
were found in age, percentage of the patients who
smoke, or those who have hypertension, diabetes
mellitus, hyperuricemia, organic heart disease, or-
ganic pulmonary disease or thromboembolism. The
percentage of patients treated with angiotensin
converting-enzyme inhibitor or angiotensin receptor
antagonist did not diﬀer between the 2 groups. The
percentage of women was greater in the pravastatin
Table 1 Clinical characteristics of patients.
Pravastatin (+) group (N = 41) Pravastatin () group (N = 277) P-value
Age (yr) 69:7 8:9 68:7 12:0 N.S.
Male:female 18:23 203:74 P < 0:01
Smoking 9 (22.0%) 85 (30.7%) N.S.
Hypertension 16 (34.0%) 123 (44.4%) N.S.
Diabetes mellitus 3 (7.3%) 39 (14.1%) N.S.
Hyperuricemia 4 (9.8%) 17 (6.1%) N.S.
Alcohol 9 (22.0%) 139 (50.2%) P < 0:01
Organic heart disease 12 (29.3%) 91 (32.9%) N.S.
Organic pulmonary disease 4 (9.8%) 24 (8.7%) N.S.
Thromboembolism 9 (22.0%) 55 (19.9%) N.S.
ACE-inhibitor 8 (19.5%) 73 (26.4%) N.S.
Observed period (months) 50:9 37:4 48:0 30:0 N.S.
Suffering period (months) 16:0 22:5 17:0 28:1 N.S.
LVDd (mm) 46:1 5:3 45:9 5:9 N.S.
LAD (mm) 34:6 6:8 34:2 6:3 N.S.
LVEF (%) 70:5 10:0 68:3 11:3 N.S.
ANP during SR (pg/ml) 36:7 36:3 42:2 40:7 N.S.
CRP (mg/dl) 0:17 0:21 0:17 0:19 N.S.
Cholesterol (mg/dl) 193:6 42:7 198:3 26:5 N.S.
Triglyceride (mg/dl) 163:5 41:5 144:7 42:9 N.S.
Onset of Paroxysmal AF;
Diurnal:nocturnal:mixed 9:15:17 46:91:140 N.S.
Continuous values are mean  SD. Values in parentheses are %.
Abbreviations: ACE, angiotensin converting enzyme; LVDd, left ventricular end-diastolic dimension; LAD, left atrial dimension;
LVEF, left ventricular ejection fraction; ANP, atrial natriuretic peptide; SR, sinus rhythm; CRP, C-reactive protein.
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(+) group than in the pravastatin () group, while
the percentage of patients with an alcohol habits
was signiﬁcantly greater in the pravastatin () group
than in the pravastatin (+) group (both P < 0.01).
There were no signiﬁcant diﬀerences between the 2
groups in the observation period, history of AF, left
ventricular end-diastolic dimension (LVDd), left
atrial dimension (LAD) or LVEF determined by
echocardiography, ANP during sinus rhythm (SR),
plasma concentrations of C-reactive protein (CRP),
cholesterol, or triglyceride, or onset of paroxysmal
AF. Plasma cholesterol concentration in the pravas-
tatin (+) group was 243:5 23:9mg/dl at baseline
with a signiﬁcant (P < 0.01) reduction to 193:6
42:7mg/dl after therapy. As anti-thrombotic ther-
apy, warfarin was administered in 148 patients and
aspirin (81–100mg/day) in 101 patients.
Recurrence of AF after Therapy with Anti-
arrhythmic Agent
The rate of recurrence of AF in the individual
patients during the follow-up period was 1:4 1:8 in
the pravastatin (+) group, and 1:5 2:0 in the
pravastatin () group. There was no signiﬁcant
diﬀerence between the 2 groups.
Rate of Sinus Rhythm Maintenance
The actuarial rates for the maintenance of sinus
rhythm in the 2 groups are shown in Figure 1. At 60
months, the survival rate of patients who did not
have permanent AF was 93% in the pravastatin (+)
group, and 79% in the pravastatin () group. There
was a statistically signiﬁcant diﬀerence between the
2 groups (P = 0.0348). Relative risk reduction of
conversion to permanent AF was 3.43 (95% con-
ﬁdence limits: 3.32–3.54). in the pravastatin (+)
group. Seventy patients (25.3%) (men: 50, women:
20) in the pravastatin () group, and only 4 patients
(9.8%) (men: 3, women: 1) in the pravastatin (+)
group eventually developed permanent AF during
the follow-up period. There was a signiﬁcant diﬀer-
ence in the rate between the 2 groups (P = 0.029,
Figure 2).
Transthoracic Echocardiographic Findings at
Baseline and after Therapy
Echocardiography was performed at baseline and
after therapy in 31 cases in the pravastatin (+) group.
The mean follow-up period was 39:4 23:2 months.
There was no signiﬁcant diﬀerence in LVDd, LAD,
and LVEF determined by echocardiography between
baseline and after therapy in the pravastatin (+)
group (Figure 3).
Echocardiography was performed in 153 cases
in the pravastatin () group. The mean follow-
up period was 38:3 23:6 months. There was no
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Figure 1 Event free rate for the onset of permanent AF in all patients with paroxysmal atrial ﬁbrillation.
Abscissa: follow-up period (months). Ordinate: rate of patients maintaining sinus rhythm (%). Straight line and dotted line
indicate changes in the rate of patients maintaining sinus rhythm in pravastatin (+) group and pravastatin () group,
respectively. Note that the rate of patients maintaining sinus rhythm in the pravastatin group was signiﬁcantly greater than
that in the pravastatin () group (p < 0.05; 2-test).
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Figure 3 Changes in left ventricu-
lar end-diastolic dimension (LVDd),
left atrial dimension (LAD), and left
ventricular ejection fraction (LVEF)
in 31 patients with paroxysmal AF
determined by echocardiography at
baseline and after therapy treated
with pravastatin therapy.
Average follow-up period: 39:4 23:2
months. Note that all markers deter-
mined were unaltered in the pravastatin
(+) group.
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Figure 2 Comparison of patients with par-
oxysmal AF who developed permanent AF
despite therapy at 60 weeks in the pravastatin
(+) and pravastatin () groups.
Note that the rate of patients converting to
permanent AF in the pravastatin (+) group was
signiﬁcantly lower than in the pravastatin ()
group (p < 0.05; 2-test).
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Figure 4 Changes in left ventricu-
lar end-diastolic dimension (LVDd),
left atrial dimension (LAD), and left
ventricular ejection fraction (LVEF)
in 153 patients with paroxysmal AF
determined by echocardiography at
baseline and after treatment with
antiarrhythmic agents alone.
Average follow-up period: 38:3 23:6
months. Note that LAD after therapy
was signiﬁcantly increased in the pra-
vastatin () group compared to base-
line.
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signiﬁcant diﬀerence in LVDd and LVEF between
baseline and post-therapy in this group, whereas,
LAD was signiﬁcantly greater post-therapy than at
baseline (P < 0.01, Figure 4).
Discussion
Atrial biopsy in patients with lone AF which is
refractory to anti-arrhythmic agents for maintenance
of sinus rhythm reveals pathological changes such
as inﬁltration of inﬂammatory cells, necrosis, and
ﬁbrosis.4,13,14) Chronic inﬂammation of atrial myo-
cardium is thus implicated in the pathogenesis of
AF. According to studies using sterile pericarditis
in experimental animal models, electrophysiological
properties of AF such as a shortened refractory
period and reduction of conduction velocity in
which AF can easily be induced and prolonged are
developed by inﬂammation of the atrium. Namely,
inﬂammation contributes strongly to the formation
of an arrhythmogenic substrate providing a reentry
circuit in AF. Statins have been shown to prolong
a shortened refractory period, to improve a delays
in intra-atrial conduction, and to prevent ﬁbrosis of
atrial myocardium,15) possibly due to their anti-
inﬂammatory eﬀects. According to epidemiological
investigations performed in Europe and the USA, the
elevation of plasma concentrations of CRP, a marker
of inﬂammatory responses, is considered a high risk
factor for myocardial infarction and cerebral throm-
boembolism.16,17) CRP, which is elevated by vascu-
lar inﬂammation, is therefore considered to promote
tissue factor expression and to lead to a thrombosis-
prone state.18) Furthermore, the pharmacological
action of statins act on cell membranes composed
of phospholipid rather than intracellular structures
believed to modulate conduction velocity in sodium
channels and/or calcium channels located on mem-
brane surfaces,19) and to exert an anti-arrhythmic
action by suppression of reperfusion arrhythmias
following release of coronary artery ligation.20) In
a epidemiological study of cardiovascular prognosis
in patients with AF, thromboembolism occurred in
approximately 30% of all patients at least once during
their lives.21) If the long-term eﬃcacy of combination
therapy with anti-arrhythmic drugs and statins that
have an anti-thrombotic action is superior to con-
servative treatment, this strategy may reduce the
incidence of thromboembolism associated with AF.
According to studies attempted in Europe and
the USA, high-dose pravastatin (40mg/day) exerted
an anti-inﬂammatory action that reduced plasma
concentrations of CRP to an average of 17%.22)
Furthermore, another large clinical trial has shown
that statins signiﬁcantly reduced recurrence of
ventricular tachycardia in patients with severe
ventricular dysfunction.23) In the present study,
pravastatin at the standard dose recommended in
Japan (10mg/day), enhanced the eﬀect of anti-
arrhythmic agents preventing conversion to perma-
nent AF, although recurrence of AF was not
remarkably ameliorated remarkably. Since under-
lying heart diseases enhance the development of
structural remodeling in atrial myocardium, we
analyzed the eﬀect of combination therapy with
anti-arrhythmic agent and pravastatin in patients
with lone paroxysmal AF only. Furthermore, accord-
ing to the follow-up observation for approximately 3
years by echocardiography, LAD in the pravastatin
(+) group did not change after combination therapy,
whereas LAD after combination therapy in the
pravastatin () group was signiﬁcantly greater than
that at baseline. These ﬁndings suggests that the
development of structural remodeling in atrial
myocardium can be prevented with combination
therapy.24)
Plasma concentrations of high-sensitivity CRP at
baseline and after combination therapy were not
measured in the present study, and the standard
dose of pravastatin in Japan was relatively low at
approximately 1/4 of the dose administered in
Europe and the USA.23) It therefore remains unclear
whether the anti-inﬂammatory action of pravastatin
described above aﬀected the prevention of recur-
rence of AF and development of structural remodel-
ing in atrial myocardium in the present study. In
addition, pravastatin is shown to have pleiotropic
eﬀects such as anti-oxidant activity, protective
activity against endothelial cells, and stabilizing
activity in cellular membranes.25) The etiology of
these pleiotropic eﬀects of statins remains unclear in
the present study.
Age, underlying heart diseases, LAD, and duration
of disease, which have been reported as risk factors
for recurrence of paroxysmal AF, did not diﬀer
statistically between the 2 groups in this study.
However, as all patients in the pravastatin (+) group
had hyperlipidemia, some bias existed in the selec-
tion of subjects. Also, the total number of patients
was relatively small. This places a limitation on our
evaluation of the eﬀects of combination therapy for
prevention of recurrence of AF and development of
structural remodeling in atrial myocardium. Further
investigation through prospective and multi-center
studies will be required to assess the therapeutic
eﬃcacy of combination therapy with anti-arrhythmic
agents and pravastatin in patients with paroxysmal
AF.
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Conclusion
The addition of pravastatin to anti-arrhythmic
agents appears to enhance the eﬀects of anti-
arrhythmic agents in maintaining sinus rhythm and
preventing the development of structural remodeling
in atrial myocardium.
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